An ongoing observational registry study is evaluating Kiyatec‘s novel technology, in which a patient’s own tumor tissue is cultured in a lab dish and exposed to different therapies as a means to predict treatment response in women with ovarian cancer. The 3D-PREDICT trial (NCT03561207) is studying the company’s patient-specific Ex Vivo 3D Cell Culture (EV3D) assay as a predictor of chemotherapy responses in ovarian cancer patients whose disease is newly diagnosed or recurred after prior…
You must be logged in to read/download the full post.
The post 3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients appeared first on BioNewsFeeds.